Cargando…
Peripheral Dopamine 2-Receptor Antagonist Reverses Hypertension in a Chronic Intermittent Hypoxia Rat Model
The sleep apnea-hypopnea syndrome (SAHS) involves periods of intermittent hypoxia, experimentally reproduced by exposing animal models to oscillatory PO(2) patterns. In both situations, chronic intermittent hypoxia (CIH) exposure produces carotid body (CB) hyperactivation generating an increased inp...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402302/ https://www.ncbi.nlm.nih.gov/pubmed/32664461 http://dx.doi.org/10.3390/ijms21144893 |
_version_ | 1783566728945467392 |
---|---|
author | Olea, Elena Docio, Inmaculada Quintero, Miguel Rocher, Asunción Obeso, Ana Rigual, Ricardo Gomez-Niño, Angela |
author_facet | Olea, Elena Docio, Inmaculada Quintero, Miguel Rocher, Asunción Obeso, Ana Rigual, Ricardo Gomez-Niño, Angela |
author_sort | Olea, Elena |
collection | PubMed |
description | The sleep apnea-hypopnea syndrome (SAHS) involves periods of intermittent hypoxia, experimentally reproduced by exposing animal models to oscillatory PO(2) patterns. In both situations, chronic intermittent hypoxia (CIH) exposure produces carotid body (CB) hyperactivation generating an increased input to the brainstem which originates sympathetic hyperactivity, followed by hypertension that is abolished by CB denervation. CB has dopamine (DA) receptors in chemoreceptor cells acting as DA-2 autoreceptors. The aim was to check if blocking DA-2 receptors could decrease the CB hypersensitivity produced by CIH, minimizing CIH-related effects. Domperidone (DOM), a selective peripheral DA-2 receptor antagonist that does not cross the blood-brain barrier, was used to examine its effect on CIH (30 days) exposed rats. Arterial pressure, CB secretory activity and whole-body plethysmography were measured. DOM, acute or chronically administered during the last 15 days of CIH, reversed the hypertension produced by CIH, an analogous effect to that obtained with CB denervation. DOM marginally decreased blood pressure in control animals and did not affect hypoxic ventilatory response in control or CIH animals. No adverse effects were observed. DOM, used as gastrokinetic and antiemetic drug, could be a therapeutic opportunity for hypertension in SAHS patients’ resistant to standard treatments. |
format | Online Article Text |
id | pubmed-7402302 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74023022020-08-11 Peripheral Dopamine 2-Receptor Antagonist Reverses Hypertension in a Chronic Intermittent Hypoxia Rat Model Olea, Elena Docio, Inmaculada Quintero, Miguel Rocher, Asunción Obeso, Ana Rigual, Ricardo Gomez-Niño, Angela Int J Mol Sci Article The sleep apnea-hypopnea syndrome (SAHS) involves periods of intermittent hypoxia, experimentally reproduced by exposing animal models to oscillatory PO(2) patterns. In both situations, chronic intermittent hypoxia (CIH) exposure produces carotid body (CB) hyperactivation generating an increased input to the brainstem which originates sympathetic hyperactivity, followed by hypertension that is abolished by CB denervation. CB has dopamine (DA) receptors in chemoreceptor cells acting as DA-2 autoreceptors. The aim was to check if blocking DA-2 receptors could decrease the CB hypersensitivity produced by CIH, minimizing CIH-related effects. Domperidone (DOM), a selective peripheral DA-2 receptor antagonist that does not cross the blood-brain barrier, was used to examine its effect on CIH (30 days) exposed rats. Arterial pressure, CB secretory activity and whole-body plethysmography were measured. DOM, acute or chronically administered during the last 15 days of CIH, reversed the hypertension produced by CIH, an analogous effect to that obtained with CB denervation. DOM marginally decreased blood pressure in control animals and did not affect hypoxic ventilatory response in control or CIH animals. No adverse effects were observed. DOM, used as gastrokinetic and antiemetic drug, could be a therapeutic opportunity for hypertension in SAHS patients’ resistant to standard treatments. MDPI 2020-07-10 /pmc/articles/PMC7402302/ /pubmed/32664461 http://dx.doi.org/10.3390/ijms21144893 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Olea, Elena Docio, Inmaculada Quintero, Miguel Rocher, Asunción Obeso, Ana Rigual, Ricardo Gomez-Niño, Angela Peripheral Dopamine 2-Receptor Antagonist Reverses Hypertension in a Chronic Intermittent Hypoxia Rat Model |
title | Peripheral Dopamine 2-Receptor Antagonist Reverses Hypertension in a Chronic Intermittent Hypoxia Rat Model |
title_full | Peripheral Dopamine 2-Receptor Antagonist Reverses Hypertension in a Chronic Intermittent Hypoxia Rat Model |
title_fullStr | Peripheral Dopamine 2-Receptor Antagonist Reverses Hypertension in a Chronic Intermittent Hypoxia Rat Model |
title_full_unstemmed | Peripheral Dopamine 2-Receptor Antagonist Reverses Hypertension in a Chronic Intermittent Hypoxia Rat Model |
title_short | Peripheral Dopamine 2-Receptor Antagonist Reverses Hypertension in a Chronic Intermittent Hypoxia Rat Model |
title_sort | peripheral dopamine 2-receptor antagonist reverses hypertension in a chronic intermittent hypoxia rat model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402302/ https://www.ncbi.nlm.nih.gov/pubmed/32664461 http://dx.doi.org/10.3390/ijms21144893 |
work_keys_str_mv | AT oleaelena peripheraldopamine2receptorantagonistreverseshypertensioninachronicintermittenthypoxiaratmodel AT docioinmaculada peripheraldopamine2receptorantagonistreverseshypertensioninachronicintermittenthypoxiaratmodel AT quinteromiguel peripheraldopamine2receptorantagonistreverseshypertensioninachronicintermittenthypoxiaratmodel AT rocherasuncion peripheraldopamine2receptorantagonistreverseshypertensioninachronicintermittenthypoxiaratmodel AT obesoana peripheraldopamine2receptorantagonistreverseshypertensioninachronicintermittenthypoxiaratmodel AT rigualricardo peripheraldopamine2receptorantagonistreverseshypertensioninachronicintermittenthypoxiaratmodel AT gomezninoangela peripheraldopamine2receptorantagonistreverseshypertensioninachronicintermittenthypoxiaratmodel |